Most Recent
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.
Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.
Acciona is mulling a bid to summarily dismiss a "hopelessly flawed" patent suit by its construction partner on the troubled East Rockingham waste-to-energy plant project, saying it is doomed in light of a High Court decision holding a patentee’s rights are exhausted at the time of sale.